Kaken Pharmaceutical Co., Ltd.
Currently developing BI-4000 (novel ‘soft-anticholinergic’) For Hyperhidrosis
Exclusive License — Mar.2015
Kaken (Tokyo Stock Exchange 4521) is a Japanese specialty pharmaceutical company with a strong presence in the market of dermatology (antifungals) and orthopedics. The company’s primary areas of R&D focus include inflammation, immunology (dermatitis, rheumatoid arthritis, and osteoarthritis) pain and antifungals.